Abstract: The present disclosure provides use of Clostridium ghonii combined with a tumor angiogenesis inhibitor in preparing a pharmaceutical product for treating a tumor. The present disclosure further provides a drug for treating a tumor, where the drug includes active ingredients of Clostridium ghonii and a tumor angiogenesis inhibitor.

Abstract: A one-step nested PCR primers set and a kit modified with locked nucleic acid for detecting African swine fever virus are provided, relating to the field of molecular biology. It includes an outer primer pair, an inner primer pair and a probe. Upstream and downstream primer sequences of the outer primer pair are shown in SEQ ID NO: 1 and SEQ ID NO: 2 respectively. Upstream and downstream primer sequences are shown in SEQ ID NO: 3 and SEQ ID NO: 4 respectively. A sequence of the probe is shown in SEQ ID NO: 5. Based on the principle of nested PCR, the Tm value and stability of outer primers are improved by designing two pairs of nested primers and simultaneously modifying the outer primers with locked nucleic acid, and two independent circular nested amplification are performed, which has high sensitivity and specificity, easiness in operation and less cross contamination.

Abstract: An antigen and antibodies prepared based on peptidylarginine deiminase (PADI4) serving as a tumor marker, and application thereof are disclosed. The antigen has an amino acid sequence shown as SEQ ID NO. 1. Specific antibodies prepared by using the antigen are also disclosed. The protein PADI4 monoclonal antibodies include a protein PADI4 monoclonal antibody coated onto an ELISA plate and a biotin-labeled protein PADI4 monoclonal antibody. A kit prepared by using the antibodies of the present disclosure can effectively and stably determine a protein PADI4 level of a human serum, and has a broad spectrum, detectability, and high test repeatability.

Abstract: Application of Derivatives of Clostridium ghonii, especially in the application of Derivatives of Clostridium ghonii MW-DCG-HNCv-18 in preparation of medicines for treating non-small cell lung carcinoma. It also discloses a medicine combining the Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain with Docetaxel as the active ingredients. According to the invention, the MW-DCG-HNCv-18 strain is found to have specific inhibition effect on non-small cell lung carcinoma for the first time, the inhibition effect on the non-small cell lung carcinoma is significantly superior to that of other known similar strains, and through screening, the MW-DCG-HNCv-18 strain is found to have more prominent inhibition effect on non-small cell lung carcinoma when combined with Docetaxel injection.

Abstract: Application of Derivatives of Clostridium ghonii, especially in the application of Derivatives of Clostridium ghonii MW-DCG-HNCv-18 in preparation of medicines for treating non-small cell lung carcinoma. It also discloses a medicine combining the Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain with Docetaxel as the active ingredients. According to the invention, the MW-DCG-HNCv-18 strain is found to have specific inhibition effect on non-small cell lung carcinoma for the first time, the inhibition effect on the non-small cell lung carcinoma is significantly superior to that of other known similar strains, and through screening, the MW-DCG-HNCv-18 strain is found to have more prominent inhibition effect on non-small cell lung carcinoma when combined with Docetaxel injection.